LYMPHOPLASMACYTIC LYMPHOMA

This early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…

This study tests a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated, slow-growing types of non-Hodgkin lymphoma, including follicular lymphoma. The goal is to see if this drug pair can shrink or eliminate cancer. About 49 adults will take part. T…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests a drug called venetoclax in about 14 adults in Japan who have a rare blood cancer (Waldenström macroglobulinemia) that has returned or not responded to prior therapy. Participants take venetoclax pills daily for up to 28 months. The goal is to see if the drug can…

This study tests whether a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) given for a limited time can effectively control Waldenström's macroglobulinemia, a rare blood cancer. About 40 adults who have not yet been treated for this condition will participat…

This study compares two treatment approaches for people with previously untreated Waldenstrom's macroglobulinemia, a rare blood cancer. One group gets a BTK inhibitor (ibrutinib plus rituximab or zanubrutinib alone), while the other gets venetoclax plus rituximab. The goal is to …

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests a drug called pacritinib in 30 people with Waldenström macroglobulinemia whose cancer returned or did not respond to prior treatment. The goal is to see if the drug can shrink tumors and improve symptoms. Participants take the drug by mouth and are monitored for …

This study tests an experimental drug called MDX2003 in about 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or not improved after at least two prior treatments. The main goals are to find the safest dose and to see…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This study follows up to 1,000 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia, or related conditions to learn how these diseases progress over time. Participants receive no treatment as part of the study; instead, t…